Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Merck's CETP Inhibitor Anacetrapib Will Enter Phase III In 2008, With Cardiovascular Outcomes Study To Follow

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Company will go ahead with Phase III program after reviewing Phase III data on Pfizer's failed CETP inhibitor torcetrapib.

You may also be interested in...



Roche Takes CETP Inhibitor Into Phase III With 15,000-Patient Trial

R1658 could raise "good" cholesterol, firm says during 2007 financial review.

Roche Takes CETP Inhibitor Into Phase III With 15,000-Patient Trial

R1658 could raise "good" cholesterol, firm says during 2007 financial review.

Merck’s Positive CETP Inhibitor Study Results Could Bode Well For Drug Class

Firm has not made a final decision to move anacetrapib into Phase III trials, Merck tells "The Pink Sheet" DAILY.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS065494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By